Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement

• Published in: International journal of dermatology 2024-12, Vol.63 (12), p.1657-1667
• Main Authors: Chernyshov, Pavel Viktorovich, Tomas‐Aragones, Lucia, Zuberbier, Torsten, Kocatürk, Emek, Manolache, Liana, Pustisek, Nives, Svensson, Åke, Marron, Servando E., Sampogna, Francesca, Bewley, Anthony, Salavastru, Carmen, Koumaki, Dimitra, Augustin, Matthias, Linder, Dennis, Abeni, Damiano, Salek, Sam S., Szepietowski, Jacek C., Jemec, Gregor B.
• Format: Article
• Language: English
• Subjects: Angioedema; Clinical trials; Dermatology; Europe; Humans; measurement; Minimal Clinically Important Difference; Position measurement; Quality assessment; Quality of Life; Severity of Illness Index; Statistical analysis; Surveys and Questionnaires - statistics & numerical data; treatment; Treatment Outcome; Urticaria; Urticaria - diagnosis; Urticaria - drug therapy; Urticaria - therapy
• ISSN: 0011-9059; 1365-4632; 1365-4632
• DOI: 10.1111/ijd.17366

In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema has examined the Health‐Related Quality of Life (HRQoL) measurement in the treatment of urticaria. The Dermatology Life Quality Index was the most frequently used HRQoL instrument in clinical trials on urticaria. Many reports of clinical trials of urticaria gave no exact numeric results related to HRQoL changes, making clear conclusions and comparisons with other studies impossible. The interpretation of HRQoL impairment data is more difficult when assessed by instruments without severity stratification systems. The minimal clinically significant difference (MCID) is a more clinically oriented and relevant parameter than depending on statistically significant changes in HRQoL scores. Therefore, using HRQoL instruments with established MCID data in clinical trials and clinical practice is preferred.